Last reviewed · How we verify
Curodont D'senz
Curodont D'senz is a self-assembling peptide that promotes dentin remineralization and repair by mimicking the natural extracellular matrix structure.
Curodont D'senz is a self-assembling peptide that promotes dentin remineralization and repair by mimicking the natural extracellular matrix structure. Used for Treatment of early-stage dentin caries lesions (arrested caries management).
At a glance
| Generic name | Curodont D'senz |
|---|---|
| Also known as | Self assembling peptide containing desensitizing agent |
| Sponsor | Al-Azhar University |
| Drug class | Self-assembling peptide scaffold |
| Target | Dentin matrix / hydroxyapatite nucleation |
| Modality | Small molecule |
| Therapeutic area | Dentistry / Restorative Medicine |
| Phase | FDA-approved |
Mechanism of action
The drug contains a synthetic peptide (P 11-4) that self-assembles into a three-dimensional scaffold within demineralized dentin lesions. This scaffold guides the deposition of hydroxyapatite crystals and promotes the remineralization of carious lesions, effectively arresting or reversing early-stage dental caries without requiring traditional drilling and filling.
Approved indications
- Treatment of early-stage dentin caries lesions (arrested caries management)
Common side effects
- Tooth sensitivity
- Local irritation at application site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Curodont D'senz CI brief — competitive landscape report
- Curodont D'senz updates RSS · CI watch RSS
- Al-Azhar University portfolio CI